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The serine/threonine kinase PAK4 was identified first
as an effector molecule for the Rho GTPase Cdc42. PAK4
differs from other members of the PAK family both in
sequence and function. Previously we have shown that
an important function of this kinase is to mediate the
induction of filopodia in response to activated Cdc42.
Studies with a constitutively active PAK4 mutant have
shown that it also has a role in promoting anchorage-
independent growth, an important hallmark of onco-
genic transformation. Here we show that another func-
tion of PAK4 is to protect cells against apoptotic cell
death. Expression of wild-type or constitutively active
PAK4 delays the onset of apoptosis in response to tumor
necrosis factor a stimulation, UV irradiation, and serum
starvation. Consistent with an antiapoptotic function,
expression of PAK4 leads to an increase in phosphoryl-
ation of the proapoptotic protein Bad and an inhibition
of caspase activation.
Normal development requires a carefully controlled balance
between cell survival and cell death. Throughout development
excess cells are eliminated by the process of programmed cell
death, or apoptosis. A number of different stimuli can trigger
apoptosis in cells in culture including Fas ligand, UV irradia-
tion, serum deprivation, and cytokines such as tumor necrosis
factor a (TNFa).1 Exposure to apoptosis-inducing agents trig-
gers a series of events, often involving the caspase cysteine
proteases. For example, Fas ligand induces the activation and
cleavage of initiating caspases such as caspase-8, which in turn
leads to activation of downstream caspases including
caspases-3 and -9. Caspase-3 as well as other effector caspases
in turn cleave a number of different target proteins that play
important roles in mediating the apoptotic response (1, 2).
Caspase-8 can also activate a signaling pathway that leads to
cytochrome c release from the mitochondria. Release of cyto-
chrome c leads to activation of caspase-9 followed by cleavage
and activation of caspase-3, leading to apoptosis (2, 3). The
release of cytochrome c from the mitochondria is governed
largely by Bid and members of the Bcl-2 family. Members of the
Bcl-2 family can have both proapoptotic and antiapoptotic ac-
tivities. For example Bcl-2, Bcl-xL, Mcl-1, A1, and Bag-1 pro-
mote survival, whereas Bcl-xS, Bad, Bax, and Bak promote
apoptosis (4). The interactions between the different BCL-2
family members play an important role in determining cell
fate. For example Bcl-2 and Bcl-xL, which are located at the
mitochondrial outer membrane, promote cell survival by inhib-
iting cytochrome c release. In contrast Bad can interact with
Bcl-2 and Bcl-xL and prevent their inhibitory activities. Thus
binding of Bad to Bcl-2 and Bcl-xL stimulates the release of
cytochrome c from the mitochondria. One way that the activi-
ties of the Bcl-2 family members are regulated is by phospho-
rylation. When Bad is phosphorylated on serines 136 and 112 it
can no longer interact with Bcl-2 or Bcl-xL, cytochrome c re-
lease is inhibited, and apoptosis is prevented (5). A number of
survival signals including growth factors can lead to phospho-
rylation of Bad at both serines 136 and 112. Some of these
signals are mediated by the survival factor Akt, which phos-
phorylates Bad on serine 136 (6). In addition to Akt other
protein kinases can phosphorylate Bad. For example constitu-
tively active PAK1, a member of the PAK family of serine/
threonine kinases, was shown recently to stimulate Bad phos-
phorylation at both serines 136 and 112 (7, 8).
The PAK family members were identified originally as
molecular targets for the Rho GTPases Rac and Cdc42 (Refs.
9–14; for review see Refs. 15–17). At present four major
members of the PAK family have been identified in mamma-
lian cells, which seem to fall into two categories based on
their structures. The first category includes the closely re-
lated human PAK1, human PAK2, and mouse PAK3 and the
corresponding rat homologues aPAK, gPAK, and bPAK, re-
spectively (9, 11–13). Each of these proteins contains an
amino-terminal regulatory domain and a carboxyl-terminal
kinase domain. Within the regulatory domain is a GTPase
binding domain (GBD) that mediates binding to Cdc42 and
Rac. Also within the regulatory domain are two to five pro-
line-rich regions that bind to SH3 domain-containing pro-
teins such as the adaptor protein Nck (18, 19) and the ex-
change factors of the PIX/COOL families (20, 21). Carboxyl-
terminal to the kinase domain is a motif that can interact
with yeast G protein bg subunits, suggesting that the PAKs
might be regulated by heterotrimeric G proteins in mamma-
lian cells (22, 23). The most recently identified member of the
PAK family is PAK4, which falls into a second category of
PAKs (14). Like the other PAKs, PAK4 contains an amino-
terminal GBD and a carboxyl-terminal kinase domain. Un-
like other PAKs, however, PAK4 does not have SH3-domain
recognition sites or a G protein bg binding domain, and it
does not bind to PIX or Nck ( Ref. 14).2 Furthermore the GBD
and kinase domains of PAK4 have only ;50% identity with
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those of PAKs 1, 2, and 3, and the regulatory domain of PAK4
outside of the GBD is completely different from the other
PAKs.
One important function of the PAK proteins is the regulation
of cytoskeletal architecture (24–27). PAK1 has been reported to
induce filopodia and membrane ruffles by a mechanism that is
independent of its ability to bind the Rho GTPases and par-
tially independent of its kinase activity (28, 29). Others have
found that aPAK and PAK2 do not induce filopodia or lamelli-
podia but instead have a role in the dissolution of stress fibers,
down-regulation of focal adhesions, and cell retraction (30).
More recently the PAKs have been shown also to have impor-
tant roles in regulating the apoptotic response, although the
different PAKs have different functions. For example gPAK
and PAK2 get cleaved during apoptosis most likely by
caspase-3. This leads to their activation, and the activated
kinases in turn are thought to contribute to morphological and
membrane changes that occur during apoptosis (31–33). In
contrast PAK1, which is not cleaved by caspases, was reported
to protect cells from apoptosis induced by serum withdrawal in
fibroblasts and interleukin-3 withdrawal in lymphoid cells (7,
8). The survival signal induced by PAK1 is apparently due to
phosphorylation of Bad on both serines 112 and 136 (7, 8).
PAK4 was identified originally on the basis of its role as a
cytoskeletal regulatory protein. It is the first member of the
PAK family that was shown to be a link between Cdc42 and
filopodia formation (14). More recently we have found that
PAK4 also has a role in regulating cell growth. In fact a con-
stitutively active mutant of PAK4 can induce anchorage-inde-
pendent growth, one of the hallmarks of oncogenic transforma-
tion.3 Here we have investigated another role for PAK4: the
induction of cell survival pathways in response to apoptotic
stimuli. We have found that cells overexpressing either wild-
type or constitutively active PAK4 have a survival advantage
during apoptosis. PAK4 protects cells from apoptosis not only
in response to serum withdrawal but also in response to TNFa
treatment or UV irradiation. Expression of PAK4 inhibits ac-
tivation of caspase-3-like enzymes and specifically promotes
the phosphorylation of Bad on serine 112.
EXPERIMENTAL PROCEDURES
Plasmids—To construct pLPC-HA-PAK4wt, HA-PAK4wt (14) was
removed form pBluescript KS II(1) as a HindIII-StuI fragment and
inserted into the HindIII-EcoRI (blunted) site of the pLPC vector. The
pLPC vector is a retroviral expression vector with a puromycin resist-
ance marker (a gift from R. Prywes). pCAN-Myc-PAK4(S445N,S474E)
is cloned into the EcoRI site of the pCAN-Myc2 vector as described.3
This constitutively active PAK4 mutant contains a serine to glutamate
mutation at amino acid 474, the putative autophosphorylation site, and
a serine to asparagine mutation at amino acid 445. Both mutations
were generated using site-directed mutagenesis (Stratagene Quick-
Change kit). The mutation at amino acid 474 is thought to mimic a
phosphorylated amino acid, and the mutation at amino acid 445 is
thought to stabilize the catalytic loop as described.3 The Bad-glutathi-
one S-transferase (GST) fusion mammalian expression plasmid (pEBG-
Bad) was obtained from New England Biolabs.
Reagents and Antibodies—Cycloheximide (CHX), propidium iodide,
and Hoechst 33258 reagent (bis-benzimide) were from Sigma. Human
recombinant TNFa was from R&D Systems. AlexaTM488 conjugated
phalloidin (A-12379) was from Molecular Probes, Inc. Histone H4 was
from Roche Molecular Biochemicals. Bacterially expressed, purified
recombinant GST fusion-human Bad was kindly provided by T. Franke.
Mouse monoclonal anti-HA antibody (HA.11, clone 16B12) was from
Covance, and mouse monoclonal anti-c-Myc antibody (sc-40, clone
9E10) was from Santa Cruz Biotechnology. Mouse monoclonal anti-
human PARP (clone 4C10–5) was from PharMingen. Rabbit polyclonal
antibodies to phosphorylated Bad were from New England Biolabs.
Mouse monoclonal anti-GST antibody (clone GST-2) and secondary
antibodies conjugated to horseradish peroxidase were from Sigma.
Cell Culture and Transfection—NIH3T3 stably transfected with ei-
ther pLPC, PAK4, or PAK4(S445N,S474E) as described3 were grown at
37 °C in 5% CO2 and cultured in Dulbecco’s modified Eagle’s medium
(Life Technologies, Inc.) containing 10% bovine calf serum in the pres-
ence of 2 mg/ml puromycin. HeLa cells were grown in Dulbecco’s mod-
ified Eagle’s medium supplemented with 10% fetal bovine serum in the
presence of 1 mg/ml puromycin for stably transfected PAK4 and pLPC
clones. All media were supplemented with 50 units/ml penicillin, 50
mg/ml streptomycin, and 4 mM glutamine. Transient transfection assays
were carried out in HeLa cells using the calcium phosphate precipita-
tion method. HeLa stable cell lines were generated by retroviral infec-
tion. Briefly, FNX cells were transfected with pLPC empty vector, or
pLPC-HA-PAK4, by the calcium phosphate precipitation method. Su-
pernatants containing the released viruses were collected from cells 2
days after transfection and filtered through 0.45-mm filters. The virus
was used then to infect HeLa cells. Cells were selected with puromycin
(1 mg/ml), and colonies were picked ;2 weeks after selection. Expres-
sion of PAK4 was determined by Western blot and immunofluorescence
microscopy using a monoclonal antibody against the HA tag.
Survival and Apoptosis Assays—To estimate apoptosis and survival
of stably transfected cell lines, equal numbers of cells were seeded in
growth medium in 3.5-, 6-, or 10-cm plates. Two days later, cells were
stimulated as follows: for UV irradiation cells were washed twice in
phosphate-buffered saline (PBS). After removal of the PBS, cells were
exposed to 50 J/m2 UV-light in a UV cross-linker (Fisher) followed by
addition of fresh medium. For TNFa-CHX treatment cells were washed
once with fresh medium that was replaced by medium containing TNFa
and CHX either alone or together at a concentration of 10 ng/ml and 10
mg/ml, respectively. For serum deprivation experiments cells were
washed once with medium without serum, followed by addition of fresh
medium containing 0.1, 0.5, or 10% serum for 24 h.
After stimulation cells were collected at the indicated time points
(attached and floating dead cells unless otherwise indicated) and fixed
for flow cytometry analysis or used to prepare total cell extracts. To
determine the percentage of cell death by flow cytometry analysis cells
with DNA content lower than the G1 peak (sub-G1) were considered to
be apoptotic. Caspase-3-like activity was examined by Western blot
analysis of the caspase-3 substrate PARP in equal amounts of cell
lysate. Detection of the Mr 85,000 proteolytic product of PARP was used
as an indication of caspase activity.
To examine nuclear condensation, cells stained with Hoechst 33258
were analyzed by fluorescence microscopy. Cells that displayed con-
densed chromatin and blebbed nuclei were considered apoptotic. To
determine the amount of cell death in each clone apoptotic cells were
counted in the same number of viewing fields.
To determine survival rates cells were seeded in 6-well plates and
treated as described above. At the indicated time point the medium was
aspirated, and floating cells were removed by washing twice with PBS.
Attached cells were collected and counted. The survival rate is ex-
pressed in percentage of surviving cells in treated cells compared with
the untreated control.
Flow Cytometry—After stimulation cells were detached from the
plates and combined with the floating cells present in the growth
medium, collected by low speed centrifugation, washed in PBS, and
fixed in ice-cold methanol for 30 min. After washing in PBS, DNA was
stained with propidium iodide (50 mg/ml) in the presence of 50 mg/ml
RNase A for 30 min at room temperature.
The DNA content was analyzed using a FACSCalibur flow cytometer
(Becton Dickinson).
Fluorescence Microscopy—Cells were seeded in 6-well plates contain-
ing 22-mm glass coverslips and treated with TNFa-CHX as described.
At the indicated time point cells were fixed by adding 1 volume of 4%
paraformaldehyde (in PBS) to the medium and stored for 16 h at 4 °C.
Cells were washed in PBS and permeabilized with 0.1% Triton X-100 in
PBS for 20 min at room temperature. Permeabilized cells were treated
then with 10 mg/ml Hoechst 33258 in PBS (to stain the DNA) and
AlexaTM488-phalloidin (to visualize F-actin structures) for 45 min at
room temperature. Nuclear and cellular morphology was then deter-
mined using a Carl Zeiss, Inc. fluorescence microscope with appropriate
filters. Images of representative fields were taken with a digital imag-
ing device.
Western Blots—Cell extracts were obtained in M2 lysis buffer (20 mM
Tris, pH 7.6, 0.5% NP-40, 250 mM NaCl, 3 mM EDTA, 3 mM EGTA, 2 mM
dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 20 mM b-glicero-
phosphate, 1 mM Na3VO4, 1 mg/ml leupeptin) (34) and equal amounts of
proteins were separated by SDS-polyacrylamide gel electrophoresis
(PAGE), transferred to polyvinylidene difluoride membranes (Immo-
3 Qu, J., Cammarano, M. S., Shi, Q., Ha, K., de Lanerolle, P., and
Minden, A., (2001) Mol. Cell. Biol. in press.
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bilon P, Millipore Corp.), and incubated with antibodies as described in
Ref. 14.
Protein Kinase Assays—Cell lysates and immunoprecipitations for
kinase assays were performed as described in Ref. 14 using histone
H4 as a substrate. For the detection of phosphorylated Bad, cells were
lysed in M2 buffer (34), and equal amounts of proteins were used for
immunoprecipitation. Kinase assays were then performed essentially
as described in Ref. 35 with slight modifications: immunopurified
proteins were washed four times in lysis buffer, once in ice-cold water,
and once with Akt kinase buffer (20 mM Hepes, pH 7.4, 10 mM
MgCl2,10 mM MnCl2; Ref. 35). Kinase reactions were performed in
kinase buffer with 1 mM dithiothreitol and 5 mM ATP for 20 min at
30 °C in the presence of 10 mCi of [g-32P]ATP (3000 Ci/mmol).
[g-32P]ATP was omitted when phosphorylation was examined by
Western blotting. Reactions were stopped by the addition of SDS-
loading buffer, and denatured proteins were separated by SDS-
PAGE. Gels were dried and exposed to x-ray films for the detection of
radioactive-labeled proteins or processed for Western blotting.
RESULTS
Expression of PAK4 Results in a Delay in Caspase Activation
and Apoptosis in TNFa/Cycloheximide-treated Cells—To ex-
amine the function of PAK4 in cell survival pathways NIH3T3
cells and HeLa cells were generated in which either wild-type
PAK4, constitutively active PAK4(S445N,S474E),3 or empty
vector were stably expressed. Even wild-type PAK4 had kinase
activity in these cells without prior stimulation by extracellular
factors. The expression and activity of PAK4 in the stable cell
lines are illustrated in Fig. 1. To examine cell survival in the
stable cell lines HeLa cells were treated with TNFa and CHX to
induce apoptosis. (CHX was used to block the NF-kB-mediated
survival pathway induced by TNFa; Ref. 36.) As shown in Fig.
2A, in control cells, TNFa and CHX induced caspase activation
within 2 h after treatment, as demonstrated by the partial
cleavage of the caspase-3 substrate PARP. By 4 h PARP was
cleaved almost completely. In contrast in cells expressing wild-
type PAK4, PARP remained completely uncleaved 2 h after
treatment and was cleaved only partly at 4 h, indicating that
induction of caspase-3-like activity was delayed in the PAK4-
overexpressing cells. At 2 h a significant proportion of the
control cells displayed condensed nuclei indicating that they
were undergoing apoptosis, as determined by Hoechst staining
(see Fig. 2B). At this time point approximately five times more
control cells had condensed nuclei as compared with the PAK4-
expressing cells. At later time points many of the control cells
had detached from the plate, and viability was assessed by
survival assays in which the number of living cells that re-
mained attached to the surface of the dish was determined
after TNFa/CHX treatment. The survival assays revealed that
;5-fold more PAK4-expressing cells from two independent cell
lines were surviving 6 h after TNFa and CHX treatment,
FIG. 1. Expression and activity of PAK4 and PAK4(S445N,S474E)
in HeLa and NIH3T3 stable cell lines. Whole-cell lysates were prepared
from HeLa stable cell lines containing either empty vector (pLPC) or HA-
PAK4 wt (left panels) or NIH (right panels) stable cell lines containing empty
vector (pLPC), Myc-PAK4wt, or Myc-PAK4(S445N,S474E). Equal amounts
of lysates were analyzed for the expression of PAK4 proteins by Western
blotting (WB) using anti-HA antibodies (left panels) or anti-Myc antibodies
(right panels). To measure kinase activity, immunocomplex kinase assays
were carried out using histone H4 (HH4) as a substrate. Phosphorylated
histone H4 was detected by autoradiography after SDS-PAGE.
FIG. 2. Stable cell lines expressing PAK4 are resistant to TNFa-induced apoptosis. A, delay in caspase activation in PAK4 cells treated
with TNFa: HeLa pLPC (control) and PAK4 clones were treated with TNFa (10 ng/ml) and CHX (10 mg/ml) alone or together as indicated or left
untreated (2). Cells were harvested at the indicated number of hours. Whole-cell lysates were prepared and analyzed for PARP cleavage by
immunoblotting with anti-PARP antibodies (top panel). Caspase activation is indicated by the appearance of the Mr 85,000 PARP cleavage product.
The same lysates were probed with anti-HA antibodies (bottom panel) to visualize HA-PAK4 expression levels. B, nuclear condensation is reduced
in TNFa-treated PAK4 clones. Nuclear condensation after 2 h of TNFa and CHX treatment was detected by fluorescence microscopy analysis of
pLPC and PAK4 cells stained with Hoechst 33258. AlexaTM488-phalloidin was used to stain F-actin structures to help visualize cell shape. Fields
with representative numbers of apoptotic cells are shown. C, PAK4 cells show higher survival after TNFa treatment. HeLa pLPC cells and two
independent PAK4 cell lines (PAK4 clones 8 and 9) were either treated with TNFa and CHX for 6 h or left untreated. Floating dead cells were
washed away, and the cells that remained attached to the plates were trypsinized and counted. The graph shows (in percentage) the relative
numbers of cells in the treated versus untreated samples. D, the sub-G1 population is reduced in TNFa-treated PAK4 cells. HeLa pLPC (light bars)
and PAK4 (dark bars) cells were treated with TNFa and CHX as described above, cells were collected at the indicated time points, fixed, and
stained with propidium iodide, and DNA content was analyzed by flow cytometry. The percentage of cells displaying DNA content lower than the
G1 peak (sub-G1%) is shown in the graph.
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compared with the control cells (Fig. 2C). Another assay for
apoptosis is DNA fragmentation, which can be assessed by flow
cytometry analysis of propidium iodide-stained cells. A signif-
icant proportion of control cells displayed a sub-G1 DNA con-
tent after TNFa and CHX treatment, indicative of DNA frag-
mentation and apoptosis, whereas only a small percentage of
PAK4-expressing cells displayed a sub-G1 DNA content (Fig.
2D).
Delay in Apoptosis in UV-treated HeLa Cells—To see
whether the PAK4 protective effect could be extended to other
stimuli cell survival and apoptosis were analyzed after expo-
sure of cells to UV irradiation. UV irradiation induced PARP
cleavage in control cells by 6 h after exposure to UV, and near
complete cleavage of PARP was observed by 18 h. In contrast in
the PAK4-expressing cells there was no PARP cleavage after
6 h, and only partial cleavage was detectable after 18 h (see Fig.
3A). Thus similar to the TNFa-treated cells, caspase activation
seemed to be delayed in the PAK4-expressing cells. Also similar
to the TNFa-treated cells, the percentage of cells that displayed
a sub-G1 DNA content was significantly lower for the PAK4-
expressing cells compared with control cells (Fig. 3B).
Delay in Apoptosis in Serum-deprived NIH3T3 Cells—An-
other trigger of apoptosis in many cells is serum withdrawal.
Serum withdrawal induces apoptosis most likely by preventing
Akt activation and thereby preventing Bad phosphorylation
(37). To see whether PAK4 protects cells from serum withdraw-
al-induced apoptosis NIH3T3 cells expressing either empty
vector, wild-type PAK4, or a hyperactive PAK4 mutant,
PAK4(S445N,S474E)3 were grown in either complete medium
or medium containing low serum. DNA content was examined
after 24 h. Significantly fewer cells expressing PAK4 wild type
displayed a sub-G1 DNA content compared with the control
cells, and even fewer of the PAK4(S445N,S474E)-expressing
cells had a sub-G1 DNA content (Fig. 4).
TNFa-induced Dephosphorylation of Bad Is Delayed in Cell
Lines Expressing PAK4—Activated PAK1 was shown recently
to induce a protective effect against serum deprivation and
cytokine withdrawal by phosphorylating the apoptotic regula-
tory protein Bad on serines 112 and 136. We found that the
basal level of Bad phosphorylation on both serines 112 and 136
was higher in PAK4-expressing HeLa cells compared with con-
trol cells when the cells were grown in low serum (see Fig. 5,
left panels). When cells were grown in the presence of 10%
serum this difference was less noticeable because in this case
the basal levels of Bad phosphorylation were quite high even in
the control cells. However, even in the presence of serum a
significant difference between the two HeLa clones was de-
tected when the cells were treated with TNFa and CHX. When
control cells were treated with TNFa and CHX Bad phospho-
rylation on both serines 112 and 136 decreased over time (Fig.
5, right panels), suggesting that as cells undergo apoptosis Bad
phosphorylation decreases, cytochrome c is released, and
caspase-3 is activated. In cells expressing PAK4, however,
there was a significant delay in the decrease in Bad dephos-
phorylation on both sites, suggesting that one way that PAK4
can inhibit apoptosis is by causing an increase in Bad
phosphorylation.
PAK4 Phosphorylates Bad—To analyze Bad phosphorylation
by PAK4, additional cells were transfected with either empty
vector or activated PAK4(S445N,S474E). In vitro kinase assays
then were carried out in which recombinant Bad was used as a
substrate for immunopurified PAK4. The results revealed that
PAK4 phosphorylates Bad specifically on serine 112 (see Fig.
6). Phosphorylation of serine 136 that we observed in PAK4 cell
lines therefore is more likely to be an indirect effect rather than
direct phosphorylation by PAK4.
DISCUSSION
The PAK4 serine/threonine kinase was identified originally
as a molecular target of the Rho GTPase Cdc42, and one func-
tion of PAK4 is to mediate the induction of filopodia in response
to Cdc42 (14). Here we have shown that in HeLa and NIH3T3
cells, another function of PAK4 is to protect cells against apo-
ptosis. We have found that overexpression of PAK4 protects
cells against apoptosis induced by three different stimuli: se-
rum withdrawal, TNFa/CHX treatment, and UV irradiation.
PAK4 causes a delay in caspase activation, a corresponding
delay in apoptosis, and an increased overall cell survival rate in
response to these stimuli. The antiapoptotic function of PAK4
seems to be correlated with its kinase activity because a con-
FIG. 3. Stable cell lines expressing PAK4 are resistant to apo-
ptosis induced by UV irradiation. A, delay in caspase activation in
UV-treated PAK4 cells. HeLa pLPC and PAK4 clones were exposed (1)
to 50 J/m2 UV radiation (UV) or left untreated (2) and harvested at the
indicated time points. Whole-cell lysates were prepared and analyzed
for PARP cleavage (top panel). PAK4 expression levels were assessed by
Western blot analysis using anti-HA antibody (bottom panel) as de-
scribed in Fig. 2A. B, the sub-G1 population is reduced in UV-treated
PAK4 cells. HeLa pLPC and PAK4 clones were UV-treated as described
above and collected at the indicated time points. DNA content was
analyzed by flow cytometry as described in Fig. 2D. The percentage of
cells displaying DNA content lower than the G1 peak (sub-G1%) is
shown in the graph.
FIG. 4. NIH3T3 cell lines expressing PAK4 are resistant to
apoptosis induced by serum deprivation. The sub-G1 population is
reduced in serum-deprived PAK4 cells. NIH pLPC (light bars), PAK4wt
(dark bars), or PAK4(S445N,S474E) (gray bars) clones was cultured for
24 h in medium containing 10, 0.5, or 0.1% serum. Cells were collected,
and DNA content was analyzed by flow cytometry as described in Fig.
2D. The percentage of cells displaying DNA content lower than the G1
peak (sub-G1%) is shown in the graph.
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stitutively active PAK4 mutant has a stronger protective effect
than wild-type PAK4 (see Fig. 4), although even wild-type
PAK4 has kinase activity and protects cells from apoptosis.
Although all members of the PAK family are thought to be
involved in the apoptotic response, the different family mem-
bers have quite different roles. During apoptosis gPAK and
PAK2 are activated by caspase cleavage and are thought to be
involved in promoting the apoptotic response because activated
forms induce morphological changes that are typical of the
onset of apoptosis (31–33, 38). In contrast PAK1 is not cleaved
by caspases, and expression of activated PAK1 protects cells
from apoptosis triggered by serum and interleukin-3 with-
drawal (7, 8). We have found that PAK4 cleavage is not induced
upon apoptotic stimulation and that it is not cleaved by
caspase-3 in vitro (data not shown). Likewise, we have found
that both wild-type and activated PAK4 protects cells from
apoptosis. Not only does PAK4 protect cells from serum with-
drawal, but it also protects cells from TNFa- or UV irradiation-
induced apoptosis.
Because PAK4-overexpressing cell lines were resistant to
apoptotic stimuli we have examined a number of different
signaling pathways that have important roles in cell growth
and apoptosis including the c-Jun NH2-terminal kinase, p38,
extracellular signal-regulated kinase, and NF-kB pathways
(Refs. 39 and 40; data not shown). However, none of these
pathways were significantly elevated or inhibited in the PAK4-
overexpressing cells. In contrast phosphorylation of the pro-
apoptotic protein Bad was elevated in the cell lines expressing
PAK4. Phosphorylation of Bad on two critical sites, serines 112
and 136, inhibits its activity and therefore protects cells
against apoptosis (5). A number of different stimuli including
growth factors lead to phosphorylation of Bad via a pathway
that requires the serine/threonine kinase Akt, which phospho-
rylates Bad on serine 136 (5). Recently PAK1 was shown to be
activated by Akt and to phosphorylate Bad on both serines 112
and 136 (7, 8). In contrast to PAK1 we have found that PAK4
phosphorylates Bad specifically on serine 112 in in vitro kinase
assays. In the stable PAK4-expressing cell lines, however, Bad
phosphorylation on both serines 112 and 136 are increased.
The reason for the increase in phosphorylation of serine 136 in
the PAK4-expressing cell lines is not clear but is more likely to
be an indirect effect rather than direct phosphorylation by
PAK4. One possibility is that Akt may be responsible for Bad
phosphorylation on this residue. In fact we have found that in
contrast to PAK1-expressing cells (7, 8) cells expressing PAK4
show an increase in Akt phosphorylation (data not shown),
suggesting a possible increase in Akt activity. Thus although
expression of PAK4 leads to Bad phosphorylation on both
serines 112 and 136, the two sites are most likely phosphoryl-
ated by different mechanisms. Although serine 112 can be
phosphorylated directly by PAK4, serine 136 is most likely
phosphorylated by an indirect mechanism.
Caspase activation triggered by either TNFa or UV irradia-
tion is prevented or delayed in PAK4 cell lines, as detected by
PARP cleavage. This is the first demonstration that caspase
activity can be regulated by expression of a PAK protein. Be-
cause PAK4 phosphorylates Bad the most likely explanation
for this is that PAK4 prevents the release of cytochrome c from
the mitochondria by inhibiting Bad activity and thereby inhib-
its the activation of caspase-3, an effector caspase in this path-
way. Another possibility, however, is that initiator caspases are
affected. Death ligands such as TNFa activate initiator
caspases such as caspase-8, which in turn can trigger apoptosis
by either mitochondria-dependent or -independent mecha-
nisms (41). Therefore protection from TNFa-induced cell death
by PAK4 could also potentially occur at the level of initiator
caspases such as caspase-8 by a mechanism that does not
strictly require Bad phosphorylation. Although the mechanism
by which TNFa induces apoptosis is relatively well understood
(41), the molecular events that mediate UV irradiation-induced
apoptosis are quite complex. UV irradiation can stimulate
FIG. 5. TNFa induced activation of Bad is delayed in cell lines
expressing PAK4. Left panels, levels of phospho-Bad in low serum:
HeLa pLPC and PAK4 clones, transfected with GST-Bad expression
vector (pEBG-Bad), were cultured in 0.5% serum for 24 h. Equal
amounts of cell extracts were analyzed by Western blotting with anti-
bodies directed against Bad that is phosphorylated on Ser-112 or Ser-
136 either together (B) or separately (C and D, respectively). GST-Bad
expression levels were detected with anti-GST antibodies (A). Right
panels, TNFa-induced dephosphorylation of Bad is delayed in PAK4
cells. HeLa pLPC and PAK4 clones were transfected with a control
plasmid (2) or GST-Bad expression vector (1). After 36 h, cells were
treated with TNFa and CHX (TNF-CHX) for the indicated number of
hours or left untreated (2). Equal amounts of protein cell extracts were
analyzed for Bad phosphorylation by Western blotting as described
above.
FIG. 6. PAK4 phosphorylates Bad
on serine 112. HeLa cells were trans-
fected either with empty vector or Myc-
PAK4(S445N,S474E), as indicated, and
equal amounts of cell extracts were used
for in vitro kinase assays (KA): immuno-
precipitates (IP) were used in kinase reac-
tions with recombinant GST-Bad as a sub-
strate. After SDS-PAGE, phosphorylated
Bad was detected by autoradiography (32P-
GST-Bad) or by Western blotting (WB) us-
ing phospho-specific antibodies (anti-p-
Bad) recognizing residue Ser-112 (p-S112)
or Ser-136 (p-S136) separately or combined
(S1121S136). Equal amounts of sub-
strate (GST-Bad) were used in each reac-
tion, as detected with anti-GST antibodies.
PAK4(S445N, S474E) levels were detected
in whole-cell lysates (WCL) by Western
blotting with anti-c-Myc antibodies.
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apoptosis by triggering the activation of death receptors such
as TNF receptor and thereby activate a pathway similar to the
one described above for TNFa (42). However, UV can also
induce apoptosis by other mechanisms such as by DNA damage-
dependent pathways (43, 44). Thus although we have found
that PAK4 inhibits caspase cleavage induced by UV irradia-
tion, the exact role for PAK4 in UV-induced apoptosis remains
to be fully clarified.
The finding that PAK4 can cause a protective effect in cells is
especially interesting because PAK4 is a target for Cdc42. Cdc42
and other members of the Rho GTPase family have important
roles in the regulation of cell growth, proliferation, and oncogenic
transformation (45–49). Recently we have found that constitu-
tively active PAK4(S445N,S474E) can induce anchorage-inde-
pendent growth3 an important hallmark of oncogenic transfor-
mation similar to activated mutants of Cdc42 (50–52).
Furthermore, a dominant negative PAK4 mutant can inhibit
transformation by oncogenic Dbl, an exchange factor for Cdc423
These results suggest that similar to Cdc42, PAK4 also has an
important role in oncogenic transformation. The mechanisms by
which PAK4 can regulate oncogenic transformation are not en-
tirely clear. Although changes in cytoskeletal architecture and
cell adhesion are likely to be involved,3 another important aspect
of transformation is the inhibition of apoptosis. It will be inter-
esting to determine whether the antiapoptotic function of PAK4
plays a direct role in the oncogenic process.
The regulation of apoptosis also has important implications
in normal development, where extra cells are being discarded
continuously. This process is especially pronounced during
neuronal development. It is interesting that the closest known
homologue to PAK4 is a Drosophila protein called Mushroom
Body Tiny (MBT; Ref. 53). Drosophila lacking the mbt gene
show a reduced number of Kenyon cells in the mushroom body,
a structure in Drosophila brain. These studies suggest that
MBT has a role in promoting either proliferation or survival of
cells in the mushroom body. Although PAK4 is ubiquitously
expressed, it will be interesting to see whether PAK4 and MBT
share a common role in regulating cell survival either in neu-
ronal or nonneuronal cells.
Finally, the extracellular stimuli that regulate the activity of
endogenous PAK4 are not yet known. Although PAK4 is a
target for Cdc42, we do not rule out the possibility that it can
also be regulated by Cdc42-independent stimuli. Other mem-
bers of the PAK family can be regulated in fact by different
types of stimuli and can be activated by Rho GTPase-depend-
ent and -independent mechanisms (15, 16). In future work it
will be important to determine what types of stimuli can acti-
vate kinase activity in endogenous PAK4, and specifically
whether it is activated by stimuli that have a protective effect
against apoptosis.
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